Rasagiline
- rasagiline
- 136236-51-6
- (R)-N-(2-Propynyl)-2,3-dihydroinden-1-amine
- Azilect
- (R)-N-2-Propynyl-1-indanamine
- Create:2005-08-09
- Modify:2025-01-25
- 2,3-dihydro-N-2-propynyl-1H-inden-1-amine-(1R)-hydrochloride
- AGN 1135
- AGN-1135
- Azilect
- N-2-propynyl-1-indanamine
- N-propargyl-1-aminoindan mesylate
- rasagiline
- rasagiline hydrochloride
- TVP 101
- TVP 1022
- TVP-101
- TVP-1022
- TVP1022
- rasagiline
- 136236-51-6
- (R)-N-(2-Propynyl)-2,3-dihydroinden-1-amine
- Azilect
- (R)-N-2-Propynyl-1-indanamine
- (1R)-N-(prop-2-yn-1-yl)-2,3-dihydro-1H-inden-1-amine
- 1-Indanamine, N-2-propynyl-, (R)-
- TV-1030
- (R)-2,3-dihydro-N-2-propynyl-1H-inden-1-amine
- (1R)-N-prop-2-ynyl-2,3-dihydro-1H-inden-1-amine
- Azilect (TN)
- RAS
- CHEMBL887
- NSC-759639
- 1H-Inden-1-amine, 2,3-dihydro-N-2-propynyl-, (1R)-
- (1R)-N-propargylindan-1-amine
- CHEBI:63620
- 003N66TS6T
- (R)-Indan-1-yl-prop-2-ynyl-amine
- Rasagiline [INN]
- (R)-N-(prop-2-ynyl)-2,3-dihydro-1H-inden-1-amine
- MFCD00866571
- (R)-N-(Prop-2-yn-1-yl)-2,3-dihydro-1H-inden-1-amine
- Rasagiline [USAN]
- (R)-(+)-Rasagiline
- Rasagiline [USAN:INN]
- Rasagilina
- UNII-003N66TS6T
- HSDB 7699
- 1H-Inden-1-amine, 2,3-dihydro-N-2-propynyl-, (1R)
- TV 1030
- Rasagiline (Standard)
- RASAGILINE [MI]
- Rasagiline (USAN/INN)
- RASAGILINE [HSDB]
- RASAGILINE [VANDF]
- RASAGILINE [WHO-DD]
- SCHEMBL74699
- MLS006012042
- N-propargyl-1-(R)aminoindan
- RASAGILINE [EMA EPAR]
- GTPL6641
- SCHEMBL2029054
- DTXSID3041112
- RASAGILINE [ORANGE BOOK]
- BDBM10989
- RUOKEQAAGRXIBM-GFCCVEGCSA-N
- HMS3264K12
- HMS3715L12
- HMS3886N03
- HY-14605AR
- Pharmakon1600-01502333
- AC-723
- HY-14605A
- NSC759639
- NSC789038
- s5795
- AKOS006271452
- AKOS015837675
- CCG-213034
- DB01367
- FS-3130
- NSC 759639
- NSC-789038
- SMR002533187
- (1R)-N-(prop-2-yn-1-yl)indan-1-amine
- DB-001111
- NS00002143
- D08469
- EN300-150047
- AB01562963_01
- AB01562963_02
- Q420685
- SR-00000006359
- SR-00000006359-3
- BRD-K58114536-001-01-6
- BRD-K58114536-066-02-7
- (1R)-2,3-DIHYDRO-N-2-PROPYN-1-YL-1H-INDEN-1-AMINE
- 1H-INDEN-1-AMINE, 2,3-DIHYDRO-N-2-PROPYNYL-, (R)-
- 1H-INDEN-1-AMINE, 2,3-DIHYDRO-N-2-PROPYN-1-YL-, (1R)-
- 1204184-69-9
- Cytoplasm
- Membrane
H302 (100%): Harmful if swallowed [Warning Acute toxicity, oral]
H315 (100%): Causes skin irritation [Warning Skin corrosion/irritation]
H319 (100%): Causes serious eye irritation [Warning Serious eye damage/eye irritation]
H335 (100%): May cause respiratory irritation [Warning Specific target organ toxicity, single exposure; Respiratory tract irritation]
P261, P264, P264+P265, P270, P271, P280, P301+P317, P302+P352, P304+P340, P305+P351+P338, P319, P321, P330, P332+P317, P337+P317, P362+P364, P403+P233, P405, and P501
(The corresponding statement to each P-code can be found at the GHS Classification page.)
Rasagiline has been reported to cause serum enzyme elevations in a small proportion of patients treated long term, although the abnormalities were usually mild and self-limiting. Rasagiline has not been implicated in cases of acute liver injury, but such instances have been reported with other less specific MAO inhibitors.
Likelihood score: E (unlikely cause of clinically apparent liver injury).
M Chen, V Vijay, Q Shi, Z Liu, H Fang, W Tong. FDA-Approved Drug Labeling for the Study of Drug-Induced Liver Injury, Drug Discovery Today, 16(15-16):697-703, 2011. PMID:21624500 DOI:10.1016/j.drudis.2011.05.007
M Chen, A Suzuki, S Thakkar, K Yu, C Hu, W Tong. DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans. Drug Discov Today 2016, 21(4): 648-653. PMID:26948801 DOI:10.1016/j.drudis.2016.02.015
◉ Summary of Use during Lactation
No clinical use of rasagiline during breastfeeding has been reported. Rasagiline might reduce serum prolactin and interfere with milk production. An alternate drug may be preferred, especially while nursing a newborn or preterm infant.
◉ Effects in Breastfed Infants
Relevant published information was not found as of the revision date.
◉ Effects on Lactation and Breastmilk
Animal studies show that rasagiline reduces serum prolactin. The clinical relevance of these findings in nursing mothers is not known. The prolactin level in a mother with established lactation may not affect her ability to breastfeed.
Patents are available for this chemical structure:
https://patentscope.wipo.int/search/en/result.jsf?inchikey=RUOKEQAAGRXIBM-GFCCVEGCSA-N
- Avoid St. John's Wort. Co-administration of rasagiline with this herb is contraindicated.
- Avoid tyramine-containing foods and supplements. Avoid food containing high amounts of tyramine (>150mg) as these may increase the risk of hypertensive reaction. Tyramine-containing foods include cheese, red wine, fava beans, pickled food, cured food, and alcoholic beverages.
- Take with or without food.
- BindingDBLICENSEAll data curated by BindingDB staff are provided under the Creative Commons Attribution 3.0 License (https://creativecommons.org/licenses/by/3.0/us/).https://www.bindingdb.org/rwd/bind/info.jsp(1R)-N-(prop-2-yn-1-yl)-2,3-dihydro-1H-inden-1-aminehttps://www.bindingdb.org/rwd/bind/chemsearch/marvin/MolStructure.jsp?monomerid=10989
- Drug Gene Interaction database (DGIdb)LICENSEThe data used in DGIdb is all open access and where possible made available as raw data dumps in the downloads section.http://www.dgidb.org/downloadsRASAGILINEhttps://www.dgidb.org/drugs/rxcui:134748
- DrugBankLICENSECreative Common's Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/legalcode)https://www.drugbank.ca/legal/terms_of_useRasagilinehttps://www.drugbank.ca/drugs/DB01367
- IUPHAR/BPS Guide to PHARMACOLOGYLICENSEThe Guide to PHARMACOLOGY database is licensed under the Open Data Commons Open Database License (ODbL) https://opendatacommons.org/licenses/odbl/. Its contents are licensed under a Creative Commons Attribution-ShareAlike 4.0 International License (http://creativecommons.org/licenses/by-sa/4.0/)https://www.guidetopharmacology.org/about.jsp#licenseGuide to Pharmacology Target Classificationhttps://www.guidetopharmacology.org/targets.jsp
- Therapeutic Target Database (TTD)
- CAS Common ChemistryLICENSEThe data from CAS Common Chemistry is provided under a CC-BY-NC 4.0 license, unless otherwise stated.https://creativecommons.org/licenses/by-nc/4.0/
- ChemIDplusRasagiline [USAN:INN]https://pubchem.ncbi.nlm.nih.gov/substance/?source=chemidplus&sourceid=0136236516ChemIDplus Chemical Information Classificationhttps://pubchem.ncbi.nlm.nih.gov/source/ChemIDplus
- DTP/NCILICENSEUnless otherwise indicated, all text within NCI products is free of copyright and may be reused without our permission. Credit the National Cancer Institute as the source.https://www.cancer.gov/policies/copyright-reuse
- EPA DSSToxCompTox Chemicals Dashboard Chemical Listshttps://comptox.epa.gov/dashboard/chemical-lists/
- European Chemicals Agency (ECHA)LICENSEUse of the information, documents and data from the ECHA website is subject to the terms and conditions of this Legal Notice, and subject to other binding limitations provided for under applicable law, the information, documents and data made available on the ECHA website may be reproduced, distributed and/or used, totally or in part, for non-commercial purposes provided that ECHA is acknowledged as the source: "Source: European Chemicals Agency, http://echa.europa.eu/". Such acknowledgement must be included in each copy of the material. ECHA permits and encourages organisations and individuals to create links to the ECHA website under the following cumulative conditions: Links can only be made to webpages that provide a link to the Legal Notice page.https://echa.europa.eu/web/guest/legal-noticeRasagiline (EC: 851-611-1)https://echa.europa.eu/information-on-chemicals/cl-inventory-database/-/discli/details/297595
- FDA Global Substance Registration System (GSRS)LICENSEUnless otherwise noted, the contents of the FDA website (www.fda.gov), both text and graphics, are not copyrighted. They are in the public domain and may be republished, reprinted and otherwise used freely by anyone without the need to obtain permission from FDA. Credit to the U.S. Food and Drug Administration as the source is appreciated but not required.https://www.fda.gov/about-fda/about-website/website-policies#linking
- Hazardous Substances Data Bank (HSDB)
- Human Metabolome Database (HMDB)LICENSEHMDB is offered to the public as a freely available resource. Use and re-distribution of the data, in whole or in part, for commercial purposes requires explicit permission of the authors and explicit acknowledgment of the source material (HMDB) and the original publication (see the HMDB citing page). We ask that users who download significant portions of the database cite the HMDB paper in any resulting publications.http://www.hmdb.ca/citing
- ChEBI
- FDA Pharm ClassesLICENSEUnless otherwise noted, the contents of the FDA website (www.fda.gov), both text and graphics, are not copyrighted. They are in the public domain and may be republished, reprinted and otherwise used freely by anyone without the need to obtain permission from FDA. Credit to the U.S. Food and Drug Administration as the source is appreciated but not required.https://www.fda.gov/about-fda/about-website/website-policies#linkingFDA Pharmacological Classificationhttps://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/ucm162549.htm
- LiverTox
- Open TargetsLICENSEDatasets generated by the Open Targets Platform are freely available for download.https://platform-docs.opentargets.org/licence
- ChEMBLLICENSEAccess to the web interface of ChEMBL is made under the EBI's Terms of Use (http://www.ebi.ac.uk/Information/termsofuse.html). The ChEMBL data is made available on a Creative Commons Attribution-Share Alike 3.0 Unported License (http://creativecommons.org/licenses/by-sa/3.0/).http://www.ebi.ac.uk/Information/termsofuse.htmlChEMBL Protein Target Treehttps://www.ebi.ac.uk/chembl/g/#browse/targets
- ClinicalTrials.govLICENSEThe ClinicalTrials.gov data carry an international copyright outside the United States and its Territories or Possessions. Some ClinicalTrials.gov data may be subject to the copyright of third parties; you should consult these entities for any additional terms of use.https://clinicaltrials.gov/ct2/about-site/terms-conditions#Use
- DailyMed
- Drug Induced Liver Injury Rank (DILIrank) DatasetLICENSEUnless otherwise noted, the contents of the FDA website (www.fda.gov), both text and graphics, are not copyrighted. They are in the public domain and may be republished, reprinted and otherwise used freely by anyone without the need to obtain permission from FDA. Credit to the U.S. Food and Drug Administration as the source is appreciated but not required.https://www.fda.gov/about-fda/about-website/website-policies#linking
- European Medicines Agency (EMA)LICENSEInformation on the European Medicines Agency's (EMA) website is subject to a disclaimer and copyright and limited reproduction notices.https://www.ema.europa.eu/en/about-us/legal-noticeAzilect (EMEA/H/C/000574)https://www.ema.europa.eu/en/medicines/human/EPAR/azilectRasagiline ratiopharm (EMEA/H/C/003957)https://www.ema.europa.eu/en/medicines/human/EPAR/rasagiline-ratiopharm
- Drugs and Lactation Database (LactMed)
- Drugs@FDALICENSEUnless otherwise noted, the contents of the FDA website (www.fda.gov), both text and graphics, are not copyrighted. They are in the public domain and may be republished, reprinted and otherwise used freely by anyone without the need to obtain permission from FDA. Credit to the U.S. Food and Drug Administration as the source is appreciated but not required.https://www.fda.gov/about-fda/about-website/website-policies#linking
- EU Clinical Trials Register
- NORMAN Suspect List ExchangeLICENSEData: CC-BY 4.0; Code (hosted by ECI, LCSB): Artistic-2.0https://creativecommons.org/licenses/by/4.0/RasagilineNORMAN Suspect List Exchange Classificationhttps://www.norman-network.com/nds/SLE/
- WHO Anatomical Therapeutic Chemical (ATC) ClassificationLICENSEUse of all or parts of the material requires reference to the WHO Collaborating Centre for Drug Statistics Methodology. Copying and distribution for commercial purposes is not allowed. Changing or manipulating the material is not allowed.https://www.whocc.no/copyright_disclaimer/
- National Drug Code (NDC) DirectoryLICENSEUnless otherwise noted, the contents of the FDA website (www.fda.gov), both text and graphics, are not copyrighted. They are in the public domain and may be republished, reprinted and otherwise used freely by anyone without the need to obtain permission from FDA. Credit to the U.S. Food and Drug Administration as the source is appreciated but not required.https://www.fda.gov/about-fda/about-website/website-policies#linking
- Japan Chemical Substance Dictionary (Nikkaji)
- KEGGLICENSEAcademic users may freely use the KEGG website. Non-academic use of KEGG generally requires a commercial licensehttps://www.kegg.jp/kegg/legal.htmlAnatomical Therapeutic Chemical (ATC) classificationhttp://www.genome.jp/kegg-bin/get_htext?br08303.kegTarget-based classification of drugshttp://www.genome.jp/kegg-bin/get_htext?br08310.keg
- Metabolomics Workbench
- NCI Thesaurus (NCIt)LICENSEUnless otherwise indicated, all text within NCI products is free of copyright and may be reused without our permission. Credit the National Cancer Institute as the source.https://www.cancer.gov/policies/copyright-reuseNCI Thesaurushttps://ncit.nci.nih.gov
- NIPH Clinical Trials Search of Japan
- NLM RxNorm TerminologyLICENSEThe RxNorm Terminology is created by the National Library of Medicine (NLM) and is in the public domain and may be republished, reprinted and otherwise used freely by anyone without the need to obtain permission from NLM. Credit to the U.S. National Library of Medicine as the source is appreciated but not required. The full RxNorm dataset requires a free license.https://www.nlm.nih.gov/research/umls/rxnorm/docs/termsofservice.html
- PharmGKBLICENSEPharmGKB data are subject to the Creative Commons Attribution-ShareALike 4.0 license (https://creativecommons.org/licenses/by-sa/4.0/).https://www.pharmgkb.org/page/policies
- PharosLICENSEData accessed from Pharos and TCRD is publicly available from the primary sources listed above. Please respect their individual licenses regarding proper use and redistribution.https://pharos.nih.gov/about
- Protein Data Bank in Europe (PDBe)
- RCSB Protein Data Bank (RCSB PDB)LICENSEData files contained in the PDB archive (ftp://ftp.wwpdb.org) are free of all copyright restrictions and made fully and freely available for both non-commercial and commercial use. Users of the data should attribute the original authors of that structural data.https://www.rcsb.org/pages/policies
- Springer Nature
- Thieme ChemistryLICENSEThe Thieme Chemistry contribution within PubChem is provided under a CC-BY-NC-ND 4.0 license, unless otherwise stated.https://creativecommons.org/licenses/by-nc-nd/4.0/
- Wikidatarasagilinehttps://www.wikidata.org/wiki/Q420685
- WikipediaRasagilinehttps://en.wikipedia.org/wiki/Rasagiline
- Wiley
- PubChem
- Medical Subject Headings (MeSH)LICENSEWorks produced by the U.S. government are not subject to copyright protection in the United States. Any such works found on National Library of Medicine (NLM) Web sites may be freely used or reproduced without permission in the U.S.https://www.nlm.nih.gov/copyright.htmlMonoamine Oxidase Inhibitorshttps://www.ncbi.nlm.nih.gov/mesh/68008996Neuroprotective Agentshttps://www.ncbi.nlm.nih.gov/mesh/68018696
- GHS Classification (UNECE)GHS Classification Treehttp://www.unece.org/trans/danger/publi/ghs/ghs_welcome_e.html
- MolGenieMolGenie Organic Chemistry Ontologyhttps://github.com/MolGenie/ontology/
- PATENTSCOPE (WIPO)SID 388991102https://pubchem.ncbi.nlm.nih.gov/substance/388991102
- NCBI